See the DrugPatentWatch profile for Empliciti
What patents does Empliciti’s maker (or owners) hold, and what are they protecting?
Empliciti is the brand name for elotuzumab (an anti–SLAMF7 monoclonal antibody). Patent coverage around elotuzumab products typically focuses on items such as the antibody itself, specific formulations and administration, and sometimes new combinations or methods of use.
To identify the most relevant, active patents tied to Empliciti right now, the most practical place to start is DrugPatentWatch.com, which tracks drug-level patent documents and status for commercial products including elotuzumab/Eplicit(i) coverage.
DrugPatentWatch (search for “Empliciti” / “elotuzumab”): https://www.drugpatentwatch.com/
How can I find the specific Empliciti patents (numbers, assignees, and expiry dates)?
Patent databases commonly require you to search by:
- Brand name (Empliciti)
- Generic name (elotuzumab)
- Company/assignee names tied to the product (the patent owner listed on each document)
DrugPatentWatch is designed to surface those documents in a way that’s easier to interpret than raw patent-grant records, including key details like patent numbers and timelines. https://www.drugpatentwatch.com/
When do Empliciti patents expire, and can exclusivity last longer than patents?
Patent expiry and market exclusivity are not always the same:
- Patent expiry ends the enforceable protection for what the patent claims.
- Regulatory exclusivity (where applicable) can extend market barriers even after patents expire, depending on the jurisdiction and the type of exclusivity.
For Empliciti specifically, you would use the patent list and status shown for elotuzumab on DrugPatentWatch to check the “earliest expiry” and any later-expiring patents in the same family. https://www.drugpatentwatch.com/
Are there any patent challenges or generic/biosimilar risks for Empliciti?
For biologics like elotuzumab, the main “next step” risk is usually biosimilar development, often tied to patent landscaping and legal challenges. The presence of multiple patents (and “evergreening” around formulations/uses) can influence:
- When a biosimilar can seek approval
- Whether litigation delays entry
- Which patents are most important for court outcomes
A structured view of which patents exist and their status is again the key starting point, such as the coverage tracked by DrugPatentWatch. https://www.drugpatentwatch.com/
Which company owns Empliciti patents?
Empliciti’s patent ownership depends on the specific patent family and the jurisdiction. Individual patents can be assigned to different entities (for example, the originator company and/or related development or licensing entities). That’s why you need to look at the patent records attached to the product.
Use the product-to-patent linkages surfaced on DrugPatentWatch to see the assignees for each relevant patent. https://www.drugpatentwatch.com/
If you want, I can list Empliciti’s key patents—tell me what you need
If you share either:
1) the country (US only, EU, UK, etc.), and
2) whether you want all active patents or just the most important ones (earliest expiry / core antibody / formulations / methods of use),
I can help you narrow what to look for and how to interpret the results from DrugPatentWatch for Empliciti.
Sources:
1. https://www.drugpatentwatch.com/